News

The randomized, double-blind, placebo-controlled trial is divided into two treatment arms, MN-166 and matching placebo, and includes a six-month treatment period followed by a six-month open-label extension. The

The grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI), which is a division of the National Institutes of Health (NIH). Patients suffering from IPF

The Phase IIa trial will include a total of seven experienced Alzheimer’s disease clinical trial sites in Melbourne. The company has submitted the clinical trial including the initiation

Jardiance, a once-daily, 10mg or 25mg tablet, was approved by the US Food and Drug Administration (FDA) on 1 August 2014 as an adjunct to diet and exercise

The three-chamber PN bags help in delivering these nutrients in volumes and concentrations that meet the nutritional needs of most patients. For patients who cannot digest or absorb

The new drug product, AVP-786, is a combination of deuterium modified dextromethorphan and ultra-low dose quinidine. The payment is result of the initiation of dosing by Avanir in

At the same time, Recipharm Venture Fund, the life science sector investor with a strategic interest in pharmaceutical and biotechnology companies in need of pharmaceutical development and manufacturing

The vaccines will be delivered in 2014 and 2015. This will bring the current number of delivered doses of IMVAMUNE to Canada above 100,000 doses. Following a public

In collaboration with the US Food and Drug Administration (FDA), Ipsen is releasing a second batch of Increlex in 2014. The first batch was made available for distribution